Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danegaptide - Breye Therapeutics

Next Previous
Search
Drug Profile

Danegaptide - Breye Therapeutics

Alternative Names: GAP-134; GAP-Oral; ZP 1609

Latest Information Update: 01 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Developer Breye Therapeutics; Wyeth; Zealand Pharma
  • Class Antiarrhythmics; Cytoprotectives; Dipeptides; Eye disorder therapies; Small molecules
  • Mechanism of Action Gap junction modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diabetic macular oedema
  • Phase I Wet age-related macular degeneration
  • Discontinued Atrial fibrillation; Myocardial reperfusion injury

Most Recent Events

  • 25 Jan 2024 Phase-I/II clinical trials in Diabetic macular oedema (PO)
  • 20 Apr 2023 Breye Therapeutics in-licenses Danegaptide from Zealand Pharma
  • 20 Apr 2023 Phase-I clinical trials in Diabetic retinopathy in Denmark (PO), prior to April 2023 (Breye pipeline, April 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top